restor3D raised USD $4.4 million in equity, bringing its total raised to $5.4 million since 2017. The company develops 3D-printed implants, and entered into a development and licensing agreement with SeaSpine in late 2019.
restor3d’s materials science technology complements SeaSpine’s orthobiologics portfolio. They will leverage their specialties to develop interbodies for a range of surgical approaches, while driving clinical and economic advantages.
Products arising from this collaboration are slated for launch in 2H20.
restor3D raised USD $4.4 million in equity, bringing its total raised to $5.4 million since 2017. The company develops 3D-printed implants, and entered into a development and licensing agreement with SeaSpine in late 2019.
restor3D raised USD $4.4 million in equity, bringing its total raised to $5.4 million since 2017. The company develops 3D-printed implants, and entered into a development and licensing agreement with SeaSpine in late 2019.
restor3d’s materials science technology complements SeaSpine’s orthobiologics portfolio. They will leverage their specialties to develop interbodies for a range of surgical approaches, while driving clinical and economic advantages.
Products arising from this collaboration are slated for launch in 2H20.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
